阿立哌唑联合利培酮治疗慢性精神分裂症对照研究

A controlled study on aripiprazole combined with risperidone in the treatment of chronic schizophrenia

目的评价阿立哌唑联合利培酮治疗慢性精神分裂症的疗效和安全性。方法 212例慢性精神分裂症患者随机分为阿立哌唑联合利培酮组(治疗组,105例)和利培酮组(对照组,107例)。分别于治疗前及治疗后第2,4,8周末用阳性症状和阴性症状量表(PANSS)评价疗效,副反应量表(TESS)评价药物不良反应。结果治疗组完成105例,对照组完成104例。治疗组有效率为92.38%,显著率为77.14%;对照组有效率为85.58%,显著率为66.35%,2组疗效差异无统计学意义(P>0.05)。PANSS总分减分及PANSS阴性因子减分在第2,4,8周末治疗组均优于对照组(P<0.05或P<0.01)。2组药物不良反应均较轻微,经对症处理大多能缓解,其中在震颤、静坐不能、体重增加及泌乳、月经紊乱等发生率,治疗组明显低于对照组(P<0.05)。结论利培酮联合阿立哌唑治疗慢性精神分裂症疗效良好,不良反应小,患者治疗依从性好。

Objective To evaluate the effectiveness and safety of aripi- prazole combined risperidone in the treatment of chronic schizophrenia. Methods A total of 212 patients diagnosed as chronic schizophrenia were randomly divided into aripiprazole combined risperidone group （ treatment group, n = 105 ） and risperidone group （ control group, n = 107）. Clinical effectiveness was assessed with the positive and negative syndrome scale（PANSS） and adverse reactions with the treatment emer- gent symptom scale（TESS） before treatment and at the end of the 2, 4, 8 week. Results One hundred and five patients of the treatment group and 104 patients of the control group had completed the course. The effec- tive rate and the apparent effect rate in treatment group was 92. 38% and 77. 14%, whereas that was 85.58% and 66. 35% in control group. There was no significant difference between two groups （P 〉 0. 05 ）. Ef- fectiveness of treatment group was superior to control group at the end of the 2, 4, 8 week by PANSS total scores＂ subtraction and PANSS negative scores＂ subtraction （ P 〈 0. 01 ）. Compared with control group, treatment group had significantly fewer adverse drug reaction in the symptoms of tremor, akathisia, weight gain, lactation and menstrual disorder （P 〈 0. 05）. Conclusion Aripidrazole combined risperidone are effective and safe in the treatment of chronic schizophremia.